Wikipedia -WSS

Wikipedia

author：explore 2025-10-02 19:20:09 - browse：8

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Companies helping big Covid

WSS

Cuban government calls US nuclear submarine stop a 'provocative escalation'

Digital health funding stays low as a new reality sets in

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

Pfizer's RSV vaccine recommended for approval in Europe

How are insurers handling Leqembi and related scans?

Florida babysitter arrested over hot car death, authorities say

knowledge

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Jerome Adams on the need for new antivirals for Covid

Florida babysitter arrested over hot car death, authorities say

Medical records are filled with copy

'The View' co

ChatGPT in medicine: STAT answers readers' burning questions

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Blinken talks high

entertainment

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

Grail's uphill battle for Medicare to cover its cancer screening test

Is there an 'orca uprising'? Like orcas themselves, the answer is complex.

Biden White House, tech companies launch new safeguards around emerging AI technology

Family of Gilgo Beach murder suspect releases statement: 'Devastating time'

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

leisure time

entertainment

explore

hotspot